pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 19·1 min read
save

Nourish secures $100M funding, valuation climbs to $1.75B

May 19, 2026·read at Endpoints ↗DealPositive

Nourish, a New York-based telehealth platform that connects patients with nutritionists, announced a fresh financing round.

The round raised $100 million and lifted the company's valuation to about $1.75 billion, according to a source familiar with the deal.

The new capital is expected to support expansion of its virtual nutrition services and further development of its platform.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Nourish raises $100M for virtual nutrition care”

read at Endpoints ↗
93 words · retrieved May 19
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoExclusive: Astellas partners with Boston ‘miniproteins’ startupEndpoints
  • 2h agoRapport says drug it licensed from J&J clears Phase 2 bipolar mania studyEndpoints
  • 18h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 18h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 20h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints